FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1762610359> ?p ?o ?g. }

• W1762610359 endingPage "20" @default.
• W1762610359 startingPage "9010" @default.
• W1762610359 abstract "Epidermal growth factor receptor (EGFR) mutations occur mostly in patients with lung adenocarcinoma; such patients are also more likely to express cyclooxygenase-2 (COX-2), indicating a possible relationship between EGFR mutation and COX-2. The COX-2 and EGFR pathways mutually enhance their procarcinogenic effects in different tumor types. Therefore, simultaneous EGFR and COX-2 inhibition may be a promising therapeutic approach for patients with lung adenocarcinoma. We obtained tissue and serum samples from patients with non-small cell lung cancer (NSCLC) to detect the relationship between EGFR mutation and serum COX-2 level. Subsequently, gefitinib was combined with celecoxib to investigate the efficacy of inhibition in vitro in two NSCLC cell lines: HCC827 (del E746-A750) and A549 (wild-type EGFR). The cells were treated with gefitinib or celecoxib alone or with gefitinib plus celecoxib. Cell proliferation and apoptosis were assessed and correlated with expression of COX-2 and phosphorylated (p)-EGFR. The EGFR mutation rate of the high-COX-2 patients was significantly higher than that in the low-COX-2 patients. Multivariate analysis showed that high COX-2 levels were independently associated with EGFR mutation. Celecoxib and gefitinib inhibited cell growth in both cell lines. At sufficiently high concentrations, celecoxib plus gefitinib significantly mutually enhanced their anti-proliferative and apoptotic effects in both cell lines. At low concentrations, the combination had no additional effects on A549 cells. There was increased down regulation of COX-2 and p-EGFR when both cell lines were treated with high-concentration celecoxib plus gefitinib compared to either agent alone. This study demonstrates that high serum COX-2 levels may indicate EGFR mutations and that the efficacy of combined celecoxib and gefitinib is significantly greater in NSCLC cells with EGFR mutations; at high concentrations, the combination is efficacious in wild-type NSCLC cells." @default.
• W1762610359 created "2016-06-24" @default.
• W1762610359 creator A5020025278 @default.
• W1762610359 creator A5020854396 @default.
• W1762610359 creator A5029360531 @default.
• W1762610359 creator A5031315906 @default.
• W1762610359 creator A5047716489 @default.
• W1762610359 creator A5049143445 @default.
• W1762610359 date "2015-01-01" @default.
• W1762610359 modified "2023-09-23" @default.
• W1762610359 title "Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells." @default.
• W1762610359 cites W1482218984 @default.
• W1762610359 cites W1506163818 @default.
• W1762610359 cites W1506887248 @default.
• W1762610359 cites W1685016018 @default.
• W1762610359 cites W1969849186 @default.
• W1762610359 cites W1975560535 @default.
• W1762610359 cites W1985049508 @default.
• W1762610359 cites W1988452310 @default.
• W1762610359 cites W1996433050 @default.
• W1762610359 cites W2002368928 @default.
• W1762610359 cites W2004551890 @default.
• W1762610359 cites W2008035988 @default.
• W1762610359 cites W2010174111 @default.
• W1762610359 cites W2013687281 @default.
• W1762610359 cites W2013862513 @default.
• W1762610359 cites W2017026706 @default.
• W1762610359 cites W2017249285 @default.
• W1762610359 cites W2026836485 @default.
• W1762610359 cites W2032359283 @default.
• W1762610359 cites W2036472365 @default.
• W1762610359 cites W2041456196 @default.
• W1762610359 cites W2043707891 @default.
• W1762610359 cites W2043944220 @default.
• W1762610359 cites W2051686420 @default.
• W1762610359 cites W2065362284 @default.
• W1762610359 cites W2068140447 @default.
• W1762610359 cites W2069228549 @default.
• W1762610359 cites W2073369621 @default.
• W1762610359 cites W2084078825 @default.
• W1762610359 cites W2087744847 @default.
• W1762610359 cites W2088039296 @default.
• W1762610359 cites W2091225458 @default.
• W1762610359 cites W2095618958 @default.
• W1762610359 cites W2099902447 @default.
• W1762610359 cites W2100093357 @default.
• W1762610359 cites W2105884586 @default.
• W1762610359 cites W2106293055 @default.
• W1762610359 cites W2107053205 @default.
• W1762610359 cites W2108527141 @default.
• W1762610359 cites W2111439621 @default.
• W1762610359 cites W2111662961 @default.
• W1762610359 cites W2120404354 @default.
• W1762610359 cites W2123274778 @default.
• W1762610359 cites W2125594974 @default.
• W1762610359 cites W2126853519 @default.
• W1762610359 cites W2127558096 @default.
• W1762610359 cites W2128905862 @default.
• W1762610359 cites W2129360604 @default.
• W1762610359 cites W2131905988 @default.
• W1762610359 cites W2132157071 @default.
• W1762610359 cites W2135148499 @default.
• W1762610359 cites W2135192471 @default.
• W1762610359 cites W2135374295 @default.
• W1762610359 cites W2140842285 @default.
• W1762610359 cites W2142899523 @default.
• W1762610359 cites W2146708145 @default.
• W1762610359 cites W2147753291 @default.
• W1762610359 cites W2149733252 @default.
• W1762610359 cites W2151398298 @default.
• W1762610359 cites W2153559476 @default.
• W1762610359 cites W2160982674 @default.
• W1762610359 cites W2163842885 @default.
• W1762610359 cites W2169961966 @default.
• W1762610359 cites W2186404136 @default.
• W1762610359 cites W2219978888 @default.
• W1762610359 cites W2336215030 @default.
• W1762610359 cites W2414844657 @default.
• W1762610359 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4583875" @default.
• W1762610359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26464643" @default.
• W1762610359 hasPublicationYear "2015" @default.
• W1762610359 type Work @default.
• W1762610359 sameAs 1762610359 @default.
• W1762610359 citedByCount "7" @default.
• W1762610359 countsByYear W17626103592016 @default.
• W1762610359 countsByYear W17626103592017 @default.
• W1762610359 countsByYear W17626103592018 @default.
• W1762610359 countsByYear W17626103592023 @default.
• W1762610359 crossrefType "journal-article" @default.
• W1762610359 hasAuthorship W1762610359A5020025278 @default.
• W1762610359 hasAuthorship W1762610359A5020854396 @default.
• W1762610359 hasAuthorship W1762610359A5029360531 @default.
• W1762610359 hasAuthorship W1762610359A5031315906 @default.
• W1762610359 hasAuthorship W1762610359A5047716489 @default.
• W1762610359 hasAuthorship W1762610359A5049143445 @default.
• W1762610359 hasConcept C121608353 @default.
• W1762610359 hasConcept C126322002 @default.
• W1762610359 hasConcept C170493617 @default.

• next